Brain Scientific Inc. (BRSF) Poised to Contribute to Mental Health Research; Provides Technology to Map Brain Response to Psychedelic Treatment
BRSF has partnered with Ehave to conduct research connected to biochemical biomarkers concerning psychedelic drug administration Psychedelic drugs show promise in treating neurological disorders, including chronic pain, depression, and PTSD, but more research is needed BRSF's E-Tattoo is poised to bring benefits of biomarkers to neurological and psychiatric research; allows monitoring of patient's brain activity in a non-intrusive way Brain Scientific (OTCQB: BRSF) has partnered with Ehave, Inc., a provider of digital therapeutics for the psychedelic and mental health sectors, to use data and AI algorithms to statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment…